Motif strikes a deal needed to trigger Nasdaq IPO; OncoGenex cuts more staffers to conserve cash
UK antibiotic developer Motif Bio (AIM: MTFB) may have sorted out its financial woes, for now. The biotech made a deal to float its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
